TQB2102

· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Drug timelines are a Plus or Pro feature.

13 regulatory and trial events tracked for TQB2102, covering 2024-08-20 to 2026-04-08. Get the full timeline:

Most recent: Clinical Trial Update: A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer [Phase 1, Phase 2]